GSK plc 6-K, filed Mar 14, 2023
GSK plc (GSK)
6-K
2023-03-14
For: 2023-03-14
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on March 14, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 14 March 2023, London UK
GSK announces positive pivotal phase III data for
5-in-1 Meningococcal ABCWY vaccine candidate
●
MenABCWY combination vaccine
candidate met all 11 primary endpoints of the pivotal phase III
clinical trial and
was well tolerated with a safety profile consistent
with Bexsero and Menveo
●
The primary endpoint data demonstrated statistical
non-inferiority compared to Bexsero and Menveo in individuals 10-25 years old, with the
5-in-1 vaccine candidate eliciting a clinically meaningful immune
response
●
If
approved, this 5-in-1 vaccine candidate could provide the broadest
meningococcal serogroup coverage and could lead to a simplified
immunisation schedule
GSK plc (LSE/NYSE: GSK) today announced positive headline results from the
phase III trial (NCT04502693)
evaluating the safety, tolerability, and immunogenicity of
its MenABCWY combination vaccine
candidate, administered as two doses given
six months apart in
healthy individuals aged 10-25 years. GSK's MenABCWY vaccine candidate
combines the antigenic components of its licensed meningococcal
vaccines, Bexsero (MenB)
and Menveo (MenACWY). All
primary endpoints were met, including the
non-inferiority of the vaccine candidate for all
five Neisseria
meningitides serogroups (A, B, C, W, and
Y) compared to licensed meningococcal
vaccines Bexsero and Menveo in
terms of an immune response. In addition, the vaccine candidate was
well tolerated, with a safety profile consistent
with Bexsero and Menveo.
Invasive meningococcal disease (IMD), a major cause of meningitis
and septicaemia, is
an uncommon but serious illness that can cause life-threatening
complications or even death, typically amongst previously healthy
children and adolescents.1 Among
those contracting meningococcal diseases, one in ten will die,
sometimes in as little as 24 hours, despite
treatment.2 One-in-five
survivors suffers long-term consequences, such as brain damage,
amputations, hearing loss and nervous system
problems.1
Five Neisseria
meningitides serogroups (A, B, C, W, and
Y) account for nearly all IMD cases in most of the
world.3 As
yet, no licensed combination vaccine offers protection against
these serogroups in a single vaccine. Currently, in the US, two
separate vaccines needing four injections are required to protect
against all five serogroups. This immunisation regimen, coupled
with low awareness of the disease, can lead to sub-optimal
immunisation coverage rates,
particularly for MenB, with an estimated coverage of only
approximately 31% of adolescents in the US.4
Tony Wood, Chief Scientific Officer at GSK, said: "These statistically significant phase III data
are a very encouraging step toward reducing the incidence of
meningococcal disease. In the US, routine use of a 5-in-1
meningococcal vaccine with a two-dose regimen in adolescents at 16
to 18 years of age, just before this disease's incidence peak,
could drive significant public health impact. In addition, our
5-in-1 meningococcal vaccine candidate builds on our global
leadership in meningococcal vaccines and commitment to
innovation."
GSK is working closely with regulators to review the full phase III
data set, including the supplemental Biologics License Application
for Bexsero. This clinical trial was both the
confirmatory trial for Bexsero and the phase III trial for
MenABCWY. Detailed results from this phase III trial will be
presented in a peer-reviewed publication and at upcoming scientific
meetings.
About the MenABCWY phase III trial
The trial conducted by GSK is a phase III randomised, controlled,
observer-blind, multi-country trial to evaluate the safety,
tolerability, and immunogenicity of GSK's MenABCWY vaccine
candidate. It
is part of a comprehensive programme to generate clinical evidence
on the benefits of meningococcal immunisation. The trial started in August
2020, and approximately 3,650 participants aged 10-25
were enrolled in the US, Canada, Czech Republic, Estonia, Finland,
Turkey, and Australia.
The objective of the trial was to assess the safety profile of the
MenABCWY vaccine candidate and to compare the immune responses of
the trial's participants who received two doses of the MenABCWY
vaccine candidate six months apart to the responses of those in the
control groups who received GSK's licensed
vaccines, Bexsero (MenB) and Menveo (MenACWY).
About Bexsero
Bexsero is
currently licensed or has received regulatory approval in over 50
countries, including
the US and EU, and is used in 12 national immunisation programmes
worldwide for the prevention of IMD caused
by Neisseria
meningitides serogroup
B. Bexsero is
the only MenB vaccine with trials that have demonstrated a
reduction in IMD, including vaccine effectiveness in real-world
settings. Regulatory approvals vary by country. It is approved
for individuals two months of age and older in
Europe.
In the US, Bexsero is
licensed under the Accelerated Approval pathway for
active immunisation to prevent IMD caused
by Neisseria
meningitides serogroup B in individuals
from 10 through 25 years. Approval
of Bexsero is
based on demonstrating an immune response, as measured by serum
bactericidal activity against three serogroup B strains
representative of prevalent strains in the US. The effectiveness
of Bexsero against
diverse serogroup B strains has not been
confirmed. The
US Prescribing Information is available here.
About Menveo
Menveo vaccine
for meningococcal groups A, C, Y, and W has received regulatory
approval in over 60 countries, including the US, with more than 72
million doses distributed worldwide since
2010. Menveo offers
extensive evidence of immunogenicity with a well-characterised
safety profile (consistent with similar
vaccines).
In the US, Menveo has
received regulatory approval for active immunisation to prevent IMD
caused by Neisseria
meningitides serogroups A, C, Y, and W
in individuals from 2 months through 55 years of age.
However, Menveo does
not prevent N.
meningitides serogroup B
infections. The
US Prescribing Information is available here.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540
742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Camilla
Campbell
|
+44
(0) 7803
050238
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in the company's Annual Report on Form 20-F for
2022, GSK's Q4 Results for 2022 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
References
1 ECDC, Factsheet
about meningococcal diseases. Accessed March
2023.
2. Bing Wang et al., "Case fatality rates of
invasive meningococcal disease by serogroup and age: A systematic
review and meta-analysis", in Vaccine, Volume 37, Issue 21, 9 May 2019, Pages
2768-2782. Accessed March 2023.
3 CDC. Meningococcal
Disease Causes and How It Spreads | CDC. Accessed March
2023.
4 Pingali
C, Yankey D, Elam-Evans LD, et al. National Vaccination Coverage
Among Adolescents Aged 13-17 Years - National Immunization
Survey-Teen, United States, 2021. MMWR Morb Mortal Wkly Rep 2022;
71:1101-1108.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
14, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|